Evidence map›Paper›PMID 31544823›Full record

ArticleAntibodies (Basel, Switzerland)2019

Preferential Identification of Agonistic OX40 Antibodies by Using Cell Lysate to Pan Natively Paired, Humanized Mouse-Derived Yeast Surface Display Libraries.

Angélica V Medina-Cucurella, Rena A Mizrahi, Michael A Asensio, Robert C Edgar, Jackson Leong, Renee Leong, Yoong Wearn Lim, Ayla Nelson, Ariel R Niedecken, Jan Fredrik Simons and 5 more

Open access · goldAbstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Frontiers in bioengineering and biotechnology · 2023
    Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Angélica V Medina-CucurellaDepartment of Chemical Engineering and Material Science, Michigan State University, East Lansing, MI 48824, USA. medinacu@msu.edu.
Rena A MizrahiGigaGen Inc., One Tower Place, Suite 750, South San Francisco, CA 94080, USA. rmizrahi@gigagen.com.ORCID 0000-0001-8581-2240
Michael A AsensioGigaGen Inc., One Tower Place, Suite 750, South San Francisco, CA 94080, USA. masensio@gigagen.com.
Robert C EdgarGigaGen Inc., One Tower Place, Suite 750, South San Francisco, CA 94080, USA. robert@drive5.com.
Jackson LeongGigaGen Inc., One Tower Place, Suite 750, South San Francisco, CA 94080, USA. jleong@gigagen.com.
Renee LeongGigaGen Inc., One Tower Place, Suite 750, South San Francisco, CA 94080, USA. rleong@gigagen.com.
Yoong Wearn LimGigaGen Inc., One Tower Place, Suite 750, South San Francisco, CA 94080, USA. ylim@gigagen.com.ORCID 0000-0002-8568-4901
Ayla NelsonGigaGen Inc., One Tower Place, Suite 750, South San Francisco, CA 94080, USA. anelson@gigagen.com.
Ariel R NiedeckenGigaGen Inc., One Tower Place, Suite 750, South San Francisco, CA 94080, USA. aniedecken@gigagen.com.
Jan Fredrik SimonsGigaGen Inc., One Tower Place, Suite 750, South San Francisco, CA 94080, USA. jsimons@gigagen.com.
Matthew J SpindlerGigaGen Inc., One Tower Place, Suite 750, South San Francisco, CA 94080, USA. mspindler@gigagen.com.
Kacy StadtmillerGigaGen Inc., One Tower Place, Suite 750, South San Francisco, CA 94080, USA. kstadtmiller@gigagen.com.
Nicholas WayhamGigaGen Inc., One Tower Place, Suite 750, South San Francisco, CA 94080, USA. nwayham@gigagen.com.ORCID 0000-0001-7782-0814
Adam S AdlerGigaGen Inc., One Tower Place, Suite 750, South San Francisco, CA 94080, USA. aadler@gigagen.com.ORCID 0000-0001-9301-0037
David S JohnsonGigaGen Inc., One Tower Place, Suite 750, South San Francisco, CA 94080, USA. djohnson@gigagen.com.
GigaGen (United States) · USMichigan State University · US

Funding

Plant Biotechnology for Health and SustainabilityT32GM110523 · NIGMS · MICHIGAN STATE UNIVERSITY · PI LAST, ROBERT LOUIS · 2014 to 2023
$2.2M
Next-Generation Antibody Discovery and Development TechnologyR44CA187852 · NCI · GIGAGEN, INC. · PI JOHNSON, DAVID SCOTT · 2016 to 2018
$1.6M
NCI NIH HHS R44CA187852NIGMS NIH HHS T32 GM110523
6 · The paper itself

Abstract

To discover therapeutically relevant antibody candidates, many groups use mouse immunization followed by hybridoma generation or B cell screening. One modern approach is to screen B cells by generating natively paired single chain variable fragment (scFv) display libraries in yeast. Such methods typically rely on soluble antigens for scFv library screening. However, many therapeutically relevant cell-surface targets are difficult to express in a soluble protein format, complicating discovery. In this study, we developed methods to screen humanized mouse-derived yeast scFv libraries using recombinant OX40 protein in cell lysate. We used deep sequencing to compare screening with cell lysate to screening with soluble OX40 protein, in the context of mouse immunizations using either soluble OX40 or OX40-expressing cells and OX40-encoding DNA vector. We found that all tested methods produce a unique diversity of scFv binders. However, when we reformatted forty-one of these scFv as full-length monoclonal antibodies (mAbs), we observed that mAbs identified using soluble antigen immunization with cell lysate sorting always bound cell surface OX40, whereas other methods had significant false positive rates. Antibodies identified using soluble antigen immunization and cell lysate sorting were also significantly more likely to activate OX40 in a cellular assay. Our data suggest that sorting with OX40 protein in cell lysate is more likely than other methods to retain the epitopes required for antibody-mediated OX40 agonism.

Indexed as

deep sequencinghumanized mouse antibody repertoiresOX40yeast display

Identifiers

PMID31544823
PMCPMC6640694
OpenAlexW2912857253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.